A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

作者:Jakubowiak Andrzej J; Offidani Massimo; Pegourie Brigitte; De La Rubia Javier; Garderet Laurent; Laribi Kamel; Bosi Alberto; Marasca Roberto; Laubach Jacob; Mohrbacher Ann; Carella Angelo Michele; Singhal Anil K; Tsao Claire; Lynch Mark John; Bleickardt Eric W; Jou Ying Ming; Palumbo Antonio
来源:Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 2015-05-29 to 2015-06-02.
  • 出版日期2015-5-20